English
CD19 Knockout Raji Cell Line
CD19 Knockout Raji Cell Line
Artikelnummer
BPS82166
Verpackungseinheit
2 vials
Hersteller
BPS Bioscience
Verfügbarkeit:
wird geladen...
Preis wird geladen...
Products from BPS Bioscience require a minimum order value above 400€
Applications: Use as a control in CAR-T or NK co-culture killing assays.
Background: The Raji line was established from a Burkitt's lymphoma patient. Raji cells constitutively express B cell antigens CD19, CD20, and CD22, and offer a physiologically relevant platform to evaluate cancer-directed immunotherapies such as Chimeric Antigen Receptor (CAR) T-cells.CD19 (also known as Cluster of Differentiation 19, B-lymphocyte surface antigen B4, or CVID3) is a glycoprotein expressed at the surface of B lymphocytes through most phases of B cell maturation. It is strictly required for B cell terminal differentiation. Mutations in the CD19 gene cause severe immune-deficiency syndromes associated with impaired antibody production, such as CVID3 (common variable immuno-deficiency 3). The majority of B cell malignancies express normal to high levels of CD19, making it a nearly ideal target for cancer immunotherapy. Blinatumomab, a CD19/CD3 bi-specific T cell engager (BiTE) has been approved for relapsed/refractory B precursor ALL (Acute lymphoblastic leukemia) and CD19 was the target of the first approved CAR-T cell therapy. Studies of CD19 function and expression profiles will continue to broaden our knowledge and support broader applications in cancer therapy.
Description: CD19 Knockout Raji Cell Line is a Raji cell line where CD19 (Cluster of Differentiation 19, B-lymphocyte surface antigen B4, or CVID3) has been genetically removed from Raji cells using CRISPR/Cas9 genome editing.
Host Cell Line: Raji human B lymphoblastoid cell line, derived from a patient with Burkitt lymphoma. Suspension
Mycoplasma Testing: The cell line has been screened to confirm the absence of Mycoplasma species.
Storage Stability: Cells will arrive upon dry ice and should immediately be thawed or stored in liquid nitrogen upon receipt. Do not use a -80°C freezer for long term storage. Contact technical support at support@bpsbioscience.com if the cells are not frozen in dry ice upon arrival.
Supplied As: Each vial contains ~1 x 106 cells in 1 ml of Cell Freezing Medium (BPS Bioscience #79796)
Warnings: Avoid freeze/thaw cycles
Biosafety Level: BSL-2
Applications: Use as a control in CAR-T or NK co-culture killing assays.
Background: The Raji line was established from a Burkitt's lymphoma patient. Raji cells constitutively express B cell antigens CD19, CD20, and CD22, and offer a physiologically relevant platform to evaluate cancer-directed immunotherapies such as Chimeric Antigen Receptor (CAR) T-cells.CD19 (also known as Cluster of Differentiation 19, B-lymphocyte surface antigen B4, or CVID3) is a glycoprotein expressed at the surface of B lymphocytes through most phases of B cell maturation. It is strictly required for B cell terminal differentiation. Mutations in the CD19 gene cause severe immune-deficiency syndromes associated with impaired antibody production, such as CVID3 (common variable immuno-deficiency 3). The majority of B cell malignancies express normal to high levels of CD19, making it a nearly ideal target for cancer immunotherapy. Blinatumomab, a CD19/CD3 bi-specific T cell engager (BiTE) has been approved for relapsed/refractory B precursor ALL (Acute lymphoblastic leukemia) and CD19 was the target of the first approved CAR-T cell therapy. Studies of CD19 function and expression profiles will continue to broaden our knowledge and support broader applications in cancer therapy.
Description: CD19 Knockout Raji Cell Line is a Raji cell line where CD19 (Cluster of Differentiation 19, B-lymphocyte surface antigen B4, or CVID3) has been genetically removed from Raji cells using CRISPR/Cas9 genome editing.
Host Cell Line: Raji human B lymphoblastoid cell line, derived from a patient with Burkitt lymphoma. Suspension
Mycoplasma Testing: The cell line has been screened to confirm the absence of Mycoplasma species.
Storage Stability: Cells will arrive upon dry ice and should immediately be thawed or stored in liquid nitrogen upon receipt. Do not use a -80°C freezer for long term storage. Contact technical support at support@bpsbioscience.com if the cells are not frozen in dry ice upon arrival.
Supplied As: Each vial contains ~1 x 106 cells in 1 ml of Cell Freezing Medium (BPS Bioscience #79796)
Warnings: Avoid freeze/thaw cycles
Biosafety Level: BSL-2
| Artikelnummer | BPS82166 |
|---|---|
| Hersteller | BPS Bioscience |
| Hersteller Artikelnummer | 82166 |
| Verpackungseinheit | 2 vials |
| Mengeneinheit | PAK |
| Wirt | Human |
| Produktinformation (PDF) | Download |
| MSDS (PDF) |
|
Verwandte Artikel
Markieren Sie die Artikel, um Sie dem Warenkorb hinzuzufügen oder
Immer für Sie da
Gernot Ensinger, M.Sc.
Laurent Haze
